Cargando…

Changes in Pramipexole Utilization after Introduction of the Extended-Release Formulation: A Nationwide Study in Taiwan

BACKGROUND: Real-world impact of extended-release formulations of oral drugs should ideally be evaluated in population-based health data. OBJECTIVE: To evaluate changes in utilization of the dopamine agonist pramipexole for Parkinson’s disease after the introduction of extended-release (ER) pramipex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, K. Arnold, Hsieh, Yu-Chun, Hsieh, Shu-Feng, Chen, Rou-Shayn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984130/ https://www.ncbi.nlm.nih.gov/pubmed/33067761 http://dx.doi.org/10.1007/s40801-020-00215-6

Ejemplares similares

Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease
por: Hametner, Eva-Maria, et al.
Publicado: (2012)

Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease
por: Eisenreich, Wolfram, et al.
Publicado: (2010)

Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole
por: Salawu, Fatai Kunle
Publicado: (2012)

Auditory Musical Hallucinations Associated With Extended-Release Pramipexole in an Elderly Patient With Parkinson's Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2014)

Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease
por: Shen, Zhengze, et al.
Publicado: (2018)

Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
por: Hauser, Robert A., et al.
Publicado: (2014)

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
por: Hauser, R A, et al.
Publicado: (2014)

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
por: Faddoul, Lama, et al.
Publicado: (2018)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations
por: Xiang, Wei, et al.
Publicado: (2018)

Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study
por: Zhou, Haiyan, et al.
Publicado: (2021)

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Pramipexole use and the risk of pneumonia
por: Ernst, Pierre, et al.
Publicado: (2012)

Pramipexole: new use for an old drug – the potential use of pramipexole in the treatment of restless legs syndrome
por: Benbir, Gulcin, et al.
Publicado: (2006)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Incidence, Prevalence, and Mortality of People with Psoriasis and Psoriatic Arthritis in Taiwan: A Nationwide Cohort Study
por: ISKANDAR, Ireny Y. K., et al.
Publicado: (2022)

Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?
por: Solla, Paolo, et al.
Publicado: (2013)

10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan’s National Health Insurance Research Database
por: Hsieh, Hsing-Chun, et al.
Publicado: (2017)

Burning mouth syndrome responsive to pramipexol
por: Stuginski-Barbosa, J., et al.
Publicado: (2008)

Automatic behavior and communication due to pramipexole
por: Walker, Ruth H.
Publicado: (2016)

Analysis of pramipexole dose–response relationships in Parkinson’s disease
por: Wang, Ying, et al.
Publicado: (2016)

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Input Estimation for Extended-Release Formulations Exemplified with Exenatide
por: Trägårdh, Magnus, et al.
Publicado: (2017)

Comparative Pharmacokinetics and Bioequivalence Evaluation of Two Formulations of Pramipexole Dihydrochloride Extended-Release Tablets in Healthy Chinese Subjects Under Fasted and Fed States: A Randomized, Open-Label, Single-Dose, Two-Period Crossover Clinical Trial
por: Yang, Ling, et al.
Publicado: (2023)

Update on the use of pramipexole in the treatment of Parkinson’s disease
por: Constantinescu, Radu
Publicado: (2008)

Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole
por: Ferrari-Toninelli, Giulia, et al.
Publicado: (2010)

Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease
por: Piedad, John C. P., et al.
Publicado: (2012)

Gold nanoclusters as prospective carriers and detectors of pramipexole
por: Si, Nguyen Thanh, et al.
Publicado: (2021)

Long-Term Exposures to Air Pollutants and Risk of Peripheral Arterial Occlusive Disease: A Nationwide Cohort Study in Taiwan
por: Liao, Shu-Hui, et al.
Publicado: (2022)

Asthma, corticosteroid use and schizophrenia: A nationwide population-based study in Taiwan
por: Wang, Wei-Chen, et al.
Publicado: (2017)

Formulation and Evaluation of Extended-Release Solid Dispersion of Metformin Hydrochloride
por: Patil, SA, et al.
Publicado: (2010)

Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations
por: Ena, Javier, et al.
Publicado: (2012)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Nationwide and long-term epidemiological research of snakebite envenomation in Taiwan during 2002–2014 based on the use of snake antivenoms: A study utilizing National Health Insurance Database
por: Hsu, Jen-Yu, et al.
Publicado: (2023)

Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden
por: Wolfschlag, Mirjam, et al.
Publicado: (2021)

Restless legs syndrome: differential diagnosis and management with pramipexole
por: Brindani, Francesca, et al.
Publicado: (2009)

Pramipexole effects on startle gating in rats and normal men
por: Swerdlow, Neal R., et al.
Publicado: (2009)

Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129
por: Chau, Kai-Yin, et al.
Publicado: (2013)

Effect of Venlafaxine, Pramipexole, and Valsartan on Spermatogenesis in Male Rats
por: Saleem, Uzma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0uajstrup2le73ipdggprgm6gj